Dyslipidemia
Conditions
Interventions
None listed
Sponsors
University of Occupational and Environmental Health, Japan
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The subjects include cases of dyslipidemia among patients who have visited the outpatient clinic or been admitted to the Second Department of Internal Medicine at the University of Occupational and Environmental Health Hospital. The study considers patients for whom treatment with pemafibrate XR is being evaluated, including those changing from other medications.
Exclusion criteria
Exclusion criteria: Patients who did not provide consent to participate in this study Patients with a history of hypersensitivity to any component of this drug Patients with severe hepatic impairment, cirrhosis classified as Child-Pugh B or C, or biliary obstruction Patients with gallstones Pregnant women or women who may be pregnant Patients currently receiving cyclosporine or rifampicin Any other patients deemed unsuitable for participation by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in inflammatory markers from baseline at 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in leukocyte count and differential count of leukocytes from baseline at 12 and 24 weeks Change in liver and kidney function from baseline at 12 and 24 weeks Change in serum lipids from baseline at 12 and 24 weeks Change in other blood test parameters from baseline at 12 and 24 weeks Change in oxidative stress markers from baseline at 24 weeks Occurrence of cardiovascular events through the study period | — |
Countries
Japan
Contacts
Public ContactJun-ichiro Koga
University of Occupational and Environmental Health, Japan The Second Department of Internal Medicine
Outcome results
None listed